INSIGHTS ON CLINICAL TRIAL PARTNERING

• The Vendor Selection Blunder: An Expensive Oversight In Clinical Trials

  Vendor selection isn’t just procedural — it shapes trial outcomes. Even with a solid process, missteps can ripple through timelines, budgets, and team morale. Choose wisely.

• Creating A New World In Clinical Trial Feasibility Utilizing Advanced Analytics

  Citeline utilizes several data resources to enhance feasibility strategies and help clients drive patient engagement and recruitment.

• Enhancing Investigator Training And Communication During COVID-19

  Centralizing all trial-related information, enabling seamless interaction and global team coordination through Scout Academy.

• Improving Site Efficiency With Automated Drug Resupply And Forecasting

  Interactive Response Technology (IRT) can transform site operations by replacing error-prone manual processes with real-time, automated systems that relieve some of the burden on trial sites.

• The Path Forward In Oncology Trials

  9/10/2025

  A comprehensive site support model is crucial for navigating the complexities of modern oncology trials and accelerating drug development.

• How Real-World Data On Site Costs Accelerates Clinical Trial Success

  10/23/2025

  Outdated budgeting slows oncology trials. Real-world site cost data enables faster planning, smoother startup, and better patient care through smarter, evidence-based financial decisions.

• Can Patient Liaison Services Transform Clinical Research Access?

  9/25/2025

  Patients often face invisible hurdles in research. Watch how Patient Liaison services can change the journey for participants, sites, and sponsors, making trials easier to join and stay in.

• Redefining eSource: A Smarter, Site-Centric Approach To Clinical Trial Data Capture

  3/26/2026

  Discover how AI-powered extraction and site-centric workflows improve data quality and reduce administrative burdens for research teams.

• Early Oncology Clinical Trials: Key Considerations To Plan For Success

  5/14/2025

  This presentation outlines the key success factors driving high-impact oncology drug development, with a focus on translating innovative science into clinically and commercially meaningful outcomes.